President European Atherosclerosis Society, Professor of Public Health, Imperial College London. Cardiologist focusing on preventing coronary artery disease
Today I start the Presidency of the European Atherosclerosis Society for 4 years with big shoes to fill and a challenging landscape. With the fantastic EC and office as well as collaboration of global colleagues and friends I hope to continue the success of those before me
OTC supplements claiming to offer cholesterol lowering. Vs a low dose statin in primary prevention. Overall reduction, individual response and safety . Best trial this year
So I have just been notified that I was elected to the office of President Elect of the European Atherosclerosis Society from Jan 2020 to start a 4 year term from 2021.
Thanks for the support and lots to do
So today the first UK patient outside of clinical trials received a dose of inclisiran in my clinic. The first but not the last. A small step for a man but a giant leap for mankind. Sorry not sorry but couldn’t think of anything better….
Well this is a pleasant surprise. Particularly as a non-American……to receive this award from the prestigious US National Lipid Association is a real honour. Looking forward to visiting Scottsdale in June to see US friends and colleagues and to receive this
8 years of work & the trilogy is complete. The largest global dataset on FH ever and the most impactful initiative since Medped in the 90s. Children with FH can be identified by cholesterol levels from year 2 of life if we start to screen
I am pleased to share what is an open access article from our Heymans registry. This is the largest registry of the real world use of or a PCSK9 MAb from Europe.
Pleased to share our analysis from Clear Outcomes of the benefits of Bempedoic acid on MACE in those with Diabetes. The LDL reduction in those with and without Diabetes was similar but greater absolute benefits were seen.
Great work by Mike Lincoff and all.
Are the CV benefits of Bempedoic acid predicted by the magnitude of the change in LDL-C and comparable to that achieved with statins? Answer yes!
Our latest paper on the CV benefits of Bempedoic acid from Clear Outcomes now out in JACC.
Delighted to see Julia get this published in Nature Reviews Cardiology.
Our take on Novel and Future Lipid Lowering Therapies for CVD Prevention
DOI
10.1038/s41569-023-00860-8
Almost a year after the EMA approved inclisiran, the FDA now grants inclisiran approval in the US. Exciting news for patients and colleagues in the US. Now the implementation begins. Glad to have been part of the journey
Here is our latest work. The largest international registry of real world use of PCSK9 MAb. It's open access so we hope you enjoy reading it. Published ahead of print at EHJ Quality of Care Outcomes. The HEYMANS registy
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM. Overwhelming data now for SGLT2i . Delighted to have been part of this trial. Superb leadership by
@DLBHATTMD
under difficult circumstances
Coffee in my dressing grown listening to the birds with a touch of greenery is very good for my mental health. If the weather stays like this it will be a good way to start each working day
Full pdf now published . Santorini 1 year follow up. The largest European registry of lipid lowering treatment in high and very high risk patients post ESC guidelines in 2019
Another option in the UK for our patients out today. Bempedoic acid approved by NICE . We published the largest study in 2019 and wonderful to see this reach patients.
Just over one week to Milan and EAS 2022! >2000 registered including 1400 to attend in person! We are back. Then there’s the President’s dinner.
@society_eas
@EASCongress
Really delighted to be informed that our two papers in NEJM this year from the ORION 9, 10 and 11 trials were voted joint top papers of the year by the Oligonucleotide Therapeutics Society
#imperialcollegelondon
#research
#eas
#fhsc
#innovation
Among the 13 notable articles selected by the editors of NEJM as practice changing in 2020 was our work reporting the two largest phase 3 trials of inclisiran for cholesterol lowering
Roger Williams started MedPed and brought the global community together to tackle FH. It stalled and for 23y we worked in isolation. No more . In 2015, I started the EAS FH studies Collaboration, the only global FH registry
Our work-largest ever study of HoFH. HoFH is diagnosed too late (age12) with 9% having CVD already. Global disparities with a decade of life lost, Outcomes could be improved by earlier diagnosis and greater use of 4 or more LLT.
Now, FDA announces that bempedoic acid is indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy in established cardiovascular disease or at high risk for a CVD event based on CLEAR Outcomes
If you had said to me 10 years ago I would be blissfully spending sundays working on this, then I would have called you mad. Counted 80 bunches of grapes. Enough for half a glass of wine?
The trilogy ! Three papers 3 years the largest series now on children with HeFH, HoFH, and adults with HeFH. The EAS FHSC started in 2015 is the biggest global initiative of its kind. Together with global colleagues & patients we need universal screening
Merry Christmas one and all from us to you. Hope you are spending time with the people that matter.
Hopefully we get back to what unites us than divides us.
1 yr ago I had Covid. knocked me out for 6-8/52. Fatigue, sedentary nature of home working meant weight gain & more fatigue. Found palatable way to lose calories 5 days wk, relax at weekends plus a bit more exercise. See graph. BP feel from 127/91 to 121/75
I am trying to explain to George that if he keeps falling asleep during webinars, he is not going to be invited to co-chair again.... For non cat people this is also George exercising the ancient Vulcan mind projection technique called “feed me”
Empty convention rooms, sets being built. I have butterflies in my stomach. Ever since ESC 1996 when the bug bit. Seeing the best of the best up close. What new things will we learn at AHA 19 and take back to patients. Privileged to be a part of the Faculty
So after the World Heart Today I am back in Geneva to meet the WHO in my capacity as chair of the Council for Heart Health. With our council members let’s see if we can’t get change- policy change and resources in preventing heart attacks and strokes further. Wish me luck!
Our final 1 y follow up from the SANTORINI Registry- the largest study for a while. Overall LDL-C goal attainment improves but still low 30%. Combination therapy associated with better goal attainment. We need to figure out how to implement what we have.
A lot of hard work in the background a lot of hard work ahead. What a privilege it’s been to work with this group of people in the EAS EC and in the EAS Office.
#eas
Remember to get your nominations in for the EAS EC
Really pleased for my visiting fellow DrJulia Brandts who had her first publication with us. A novel concept for public health “The cumulative exposure model” published ahead of print in Circulation today. Here is the key figure
I am not known for procrastinating or being indecisive. When you have a vision, try to change systems, you lead by example, but need buy in of others, that you are on the right path
This thank you message from my EAS office means a lot now but even more in years to come
#eas
Second work trip since the pandemic started. Starving. Had forgotten how late people eat in Greece. One more hour to go. Wish I had said yes to the bread roll on the plane instead of worrying about the carb load……
So for the 2nd time today locals at restaurants have asked me if I am from India? To which my standard very polite British response is “no I am from London but my parents were.”
Beginning to reconsider & wondering if my response should be “Do I get a discount if I say yes”…..HNY
wasn’t sure if I would be able to travel to EAS. Bedridden with back pain since Thursday. Huge thanks to Prof Duerschmied, emergency staff, MRI team, head of Neurology and Neurosurgery in Mannheim. No disc issue,facet inflammation, spasm. Here Tx to you!
We looked into a notable cholesterol sceptic’s title of honorary Prof in evidence based medicine! Turns out all you need is a credit card. Also you can get your cat a PhD from the same place. The latter is actually evidence based! Think about it!
And this is how we kicked it off! Watch just watch . We rocked and rolled and we delivered one hell of a congress for our attendees
@society_eas
@EASCongress
Full details of our simulation study on sustained time average annual control of LDL and then maintaining that over a decade through twice yearly dosing and potential population health benefits in ASCVD
Sad to hear about the passing of Prof Jim Shepherd. Former EAS President, chair of two annual congresses and of course the landmark WOSCOPS trial showing you could prevent CVD in primary prevention. RIP 😔
2021 was my first as EAS President, a tough year for everyone around the world. We innovated finding new ways to collaborate & continue our mission. Wishing everyone a safe and healthy holiday season and best for 2022
Drowning my sorrows ! Turns out the reason I didn’t get my complimentary upgrade to a suite is because Nancy Pelosi has taken all of them. Ohh well cheers to the start of the holiday